Delineating Lifetime Multimorbidity Associated with 16p13.11 Duplication: A Literature Review, Meta-Analysis, and Case Study
Jul 30, 2025·,,,,,,,,,,,,·
1 min read
Xavier, R. M.
Bian, W.
Alshammari, F.
Harner, M. K.
Dietterich, T. E.
Lichtenstein, M.
Stowe, R.
Farrell, M.
Szatkiewicz, J. P.
Shaughnessy, R. A.
Berg, J. S.
Sullivan, P. F.
Josiassen, R. C.
Abstract
The 16p13.11 duplication is a rare copy number variation (CNV) that may increase multimorbidity risk across the life span. Initial reports implicated the duplication in autism spectrum disorder, intellectual disability, and various congenital anomalies; however, it was also observed in phenotypically normal individuals suggesting incomplete penetrance or non-pathogenicity. We conducted a literature review and meta-analysis to delineate the lifetime multimorbidity associated with 16p13.11 duplication. Speech delays, developmental delays, intellectual disability, learning disability, and autistic symptoms were reported in more than 30% of cases. Musculoskeletal abnormalities and cardiovascular disorders were commonly reported. The study also includes a lifespan case report of a 71-year-old female with a history of behavioral disturbance and treatment-resistant schizophrenia, identified as being a 16p13.11 duplication carrier.
Type
Publication
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111462